MRC1 and carcinoma: In our series, 91% (20/22) of atypical hyperplasia and 98% (41/42) of carcinoma samples were MMR‐deficient, and 73% (16/22) and 86% (36/42) had second hits (Table 1) complying with the two‐hit model of tumorigenesis.